Part 4/12:
Moreover, Hims reported total revenue of $1.5 billion for the entirety of 2024, underscoring a 69% year-over-year increase, with glp-1 (a class of medications for obesity treatment) sales contributing $225 million to this figure. Excluding glp-1s, core offerings still recorded a remarkable 43% growth, signaling substantial overall progress for the business.